Toxicity of cationic lipid-ribozyme complexes in human prostate tumor cells can mimic ribozyme activity

Stephen J. Freedland, Robert W. Malone, Holger M. Borchers, Zhanna Zadourian, Jill G. Malone, Michael J. Bennett, Michael H. Nantz, Juan Hua Li, Paul H. Gumerlock, Kent L Erickson

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Prostate tumor cell lines have been shown to both produce interleukin- 6 (IL-6) and express the IL-6 receptor, suggesting a potential autocrine growth regulatory role for IL-6. We explored the role of IL-6 in the proliferation of the human prostatic carcinoma cell line, DU145, using ribozymes to inhibit IL-6 expression. Hammerhead-type ribozymes targeted against IL-6 mRNA sequences were prepared, and in vitro analyses were used to demonstrate that these molecules catalyzed the cleavage of IL-6 mRNA polynucleotide fragments. To test in situ activity, these ribozymes were transferred into DU145 cells using cationic transfection lipids, cytofectins. Treatment of cultured cells with ribozyme/cationic lipid complexes resulted in a reduction of IL-6 protein levels in the supernatant and reduced numbers of DU145 cells 48 h after treatment. However, similar results were also seen following treatment with control RNA/lipid complexes. This reduction in IL-6 levels and cell numbers was a function of the RNA/lipid complexes and was not seen with either lipid or RNA alone. Therefore, the reductions in IL-6 levels and cell numbers observed were not due to ribozyme-mediated cleavage of IL-6 mRNA, but rather reflected a dose- dependent, nonspecific toxic effect of the treatment with ribozyme/cytofectin complexes. This effect can resemble functional ribozyme activity, complicating analysis of the activity of synthetic ribozymes after transfection into cultured cells.

Original languageEnglish (US)
Pages (from-to)144-153
Number of pages10
JournalBiochemical and Molecular Medicine
Volume59
Issue number2
DOIs
StatePublished - Dec 1996

Fingerprint

Catalytic RNA
Toxicity
Tumors
Prostate
Interleukin-6
Cells
Lipids
Neoplasms
Cell Count
RNA
Messenger RNA
Transfection
Cultured Cells
Interleukin-6 Receptors
Polynucleotides
Poisons
Tumor Cell Line
Carcinoma
Cell Line

ASJC Scopus subject areas

  • Biochemistry

Cite this

Toxicity of cationic lipid-ribozyme complexes in human prostate tumor cells can mimic ribozyme activity. / Freedland, Stephen J.; Malone, Robert W.; Borchers, Holger M.; Zadourian, Zhanna; Malone, Jill G.; Bennett, Michael J.; Nantz, Michael H.; Li, Juan Hua; Gumerlock, Paul H.; Erickson, Kent L.

In: Biochemical and Molecular Medicine, Vol. 59, No. 2, 12.1996, p. 144-153.

Research output: Contribution to journalArticle

Freedland, SJ, Malone, RW, Borchers, HM, Zadourian, Z, Malone, JG, Bennett, MJ, Nantz, MH, Li, JH, Gumerlock, PH & Erickson, KL 1996, 'Toxicity of cationic lipid-ribozyme complexes in human prostate tumor cells can mimic ribozyme activity', Biochemical and Molecular Medicine, vol. 59, no. 2, pp. 144-153. https://doi.org/10.1006/bmme.1996.0080
Freedland, Stephen J. ; Malone, Robert W. ; Borchers, Holger M. ; Zadourian, Zhanna ; Malone, Jill G. ; Bennett, Michael J. ; Nantz, Michael H. ; Li, Juan Hua ; Gumerlock, Paul H. ; Erickson, Kent L. / Toxicity of cationic lipid-ribozyme complexes in human prostate tumor cells can mimic ribozyme activity. In: Biochemical and Molecular Medicine. 1996 ; Vol. 59, No. 2. pp. 144-153.
@article{af28d5f86bb549cab1455a88226d097f,
title = "Toxicity of cationic lipid-ribozyme complexes in human prostate tumor cells can mimic ribozyme activity",
abstract = "Prostate tumor cell lines have been shown to both produce interleukin- 6 (IL-6) and express the IL-6 receptor, suggesting a potential autocrine growth regulatory role for IL-6. We explored the role of IL-6 in the proliferation of the human prostatic carcinoma cell line, DU145, using ribozymes to inhibit IL-6 expression. Hammerhead-type ribozymes targeted against IL-6 mRNA sequences were prepared, and in vitro analyses were used to demonstrate that these molecules catalyzed the cleavage of IL-6 mRNA polynucleotide fragments. To test in situ activity, these ribozymes were transferred into DU145 cells using cationic transfection lipids, cytofectins. Treatment of cultured cells with ribozyme/cationic lipid complexes resulted in a reduction of IL-6 protein levels in the supernatant and reduced numbers of DU145 cells 48 h after treatment. However, similar results were also seen following treatment with control RNA/lipid complexes. This reduction in IL-6 levels and cell numbers was a function of the RNA/lipid complexes and was not seen with either lipid or RNA alone. Therefore, the reductions in IL-6 levels and cell numbers observed were not due to ribozyme-mediated cleavage of IL-6 mRNA, but rather reflected a dose- dependent, nonspecific toxic effect of the treatment with ribozyme/cytofectin complexes. This effect can resemble functional ribozyme activity, complicating analysis of the activity of synthetic ribozymes after transfection into cultured cells.",
author = "Freedland, {Stephen J.} and Malone, {Robert W.} and Borchers, {Holger M.} and Zhanna Zadourian and Malone, {Jill G.} and Bennett, {Michael J.} and Nantz, {Michael H.} and Li, {Juan Hua} and Gumerlock, {Paul H.} and Erickson, {Kent L}",
year = "1996",
month = "12",
doi = "10.1006/bmme.1996.0080",
language = "English (US)",
volume = "59",
pages = "144--153",
journal = "Molecular Genetics and Metabolism",
issn = "1096-7192",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - Toxicity of cationic lipid-ribozyme complexes in human prostate tumor cells can mimic ribozyme activity

AU - Freedland, Stephen J.

AU - Malone, Robert W.

AU - Borchers, Holger M.

AU - Zadourian, Zhanna

AU - Malone, Jill G.

AU - Bennett, Michael J.

AU - Nantz, Michael H.

AU - Li, Juan Hua

AU - Gumerlock, Paul H.

AU - Erickson, Kent L

PY - 1996/12

Y1 - 1996/12

N2 - Prostate tumor cell lines have been shown to both produce interleukin- 6 (IL-6) and express the IL-6 receptor, suggesting a potential autocrine growth regulatory role for IL-6. We explored the role of IL-6 in the proliferation of the human prostatic carcinoma cell line, DU145, using ribozymes to inhibit IL-6 expression. Hammerhead-type ribozymes targeted against IL-6 mRNA sequences were prepared, and in vitro analyses were used to demonstrate that these molecules catalyzed the cleavage of IL-6 mRNA polynucleotide fragments. To test in situ activity, these ribozymes were transferred into DU145 cells using cationic transfection lipids, cytofectins. Treatment of cultured cells with ribozyme/cationic lipid complexes resulted in a reduction of IL-6 protein levels in the supernatant and reduced numbers of DU145 cells 48 h after treatment. However, similar results were also seen following treatment with control RNA/lipid complexes. This reduction in IL-6 levels and cell numbers was a function of the RNA/lipid complexes and was not seen with either lipid or RNA alone. Therefore, the reductions in IL-6 levels and cell numbers observed were not due to ribozyme-mediated cleavage of IL-6 mRNA, but rather reflected a dose- dependent, nonspecific toxic effect of the treatment with ribozyme/cytofectin complexes. This effect can resemble functional ribozyme activity, complicating analysis of the activity of synthetic ribozymes after transfection into cultured cells.

AB - Prostate tumor cell lines have been shown to both produce interleukin- 6 (IL-6) and express the IL-6 receptor, suggesting a potential autocrine growth regulatory role for IL-6. We explored the role of IL-6 in the proliferation of the human prostatic carcinoma cell line, DU145, using ribozymes to inhibit IL-6 expression. Hammerhead-type ribozymes targeted against IL-6 mRNA sequences were prepared, and in vitro analyses were used to demonstrate that these molecules catalyzed the cleavage of IL-6 mRNA polynucleotide fragments. To test in situ activity, these ribozymes were transferred into DU145 cells using cationic transfection lipids, cytofectins. Treatment of cultured cells with ribozyme/cationic lipid complexes resulted in a reduction of IL-6 protein levels in the supernatant and reduced numbers of DU145 cells 48 h after treatment. However, similar results were also seen following treatment with control RNA/lipid complexes. This reduction in IL-6 levels and cell numbers was a function of the RNA/lipid complexes and was not seen with either lipid or RNA alone. Therefore, the reductions in IL-6 levels and cell numbers observed were not due to ribozyme-mediated cleavage of IL-6 mRNA, but rather reflected a dose- dependent, nonspecific toxic effect of the treatment with ribozyme/cytofectin complexes. This effect can resemble functional ribozyme activity, complicating analysis of the activity of synthetic ribozymes after transfection into cultured cells.

UR - http://www.scopus.com/inward/record.url?scp=0030447472&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030447472&partnerID=8YFLogxK

U2 - 10.1006/bmme.1996.0080

DO - 10.1006/bmme.1996.0080

M3 - Article

C2 - 8986637

AN - SCOPUS:0030447472

VL - 59

SP - 144

EP - 153

JO - Molecular Genetics and Metabolism

JF - Molecular Genetics and Metabolism

SN - 1096-7192

IS - 2

ER -